out by going to tea with John Brademas, and John Brademas said
he was interested in rehabilitation, and that gave me the clue.
I knew that anything that made sense would be easy to sell to John Brademan because he's extremely bright. So we'll see what happens
about that.

Well, that's about it for legislation.

Q:

I saw an article in the WALL STREET JOURNAL which struck my
eye. It was written by Dr. Winston, who's a research fellow
at Harvard Medical School, and it's titled, “war on Cancer; Trouble
in the Ranks.” He develops such things as that there isn't agreement
among doctors and scientists interested in medical research, that
there is no agreement on the approach to various things. What
comments do you make on that?

Lasker:

Well, I think this is always true when there's anything
exciting going forward. The Peer Review system has come in for
criticism from the administration, but I don't se e any better way
to handle the giving out of grants. As far as fights about how
to use the money gos, I don't know if there have been fights but
there certainly has been a lot of discussion. Most of the basic
researchers want all the money to go for basic research, and don't
realize how little has been done clinically, and the clinical
research people are relatively mild in their demands. From my
point of view, I'm for much more clinical research.

Q:

This same doctor said in his article that if the situation
wasn't corrected soon, a sizeable portion of the Advisory Board's 23